预约演示

更新于：2025-05-07

Paracoccidioidomycosis

副球菌病

更新于：2025-05-07

基本信息

别名

Almeida、BLASTOMYCOSIS, SOUTH AMERICAN、Blastomycosis, South American

+ [57]

简介

A mycosis affecting the skin, mucous membranes, lymph nodes, and internal organs. It is caused most often by Paracoccidioides brasiliensis. It is also called paracoccidioidal granuloma.

关联

项与副球菌病相关的药物

Ketoconazole

酮康唑

靶点

C14DM

作用机制

C14DM拮抗剂 [+1]

在研机构

Teikoku Seiyaku Co. Ltd. [+5]

原研机构

Janssen Pharmaceutica NV

在研适应症

内源性库欣综合征 [+13]

非在研适应症

晚期癌症 [+3]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1981-06-12

项与副球菌病相关的临床试验

NCT06523998

/ CompletedN/AIIT

Retrospective Descriptive Observational Study of the Epidemiological, Clinical and Therapeutic Profile of Patients With Rare Infections of Dermatological Interest at Three Major Reference Hospitals in Costa Rica From 2019-2023

In Costa Rica there are some descriptive studies of some of these rare infectious diseases (sporotrichosis, chromomycosis and mycetomas); however, there are no recent published reports. Most of the publications on the subject date back to the previous century; from 2000 to the present year there are only publications of small series of cases, so the current behavior of these skin infections is unknown. The primary objective is to analyze the epidemiological, clinical, and therapeutic profile and determine the risk factors in patients with a diagnosis of rare infections of dermatological interest treated at Hospital México, Hospital Rafael Calderón Guardia, and Hospital San Juan de Dios during the period 2019-2023.

开始日期2023-12-11

申办/合作机构-

DRKS00022878

/ CompletedN/AIIT

A multicenter study to increasedrug safety concerning the usage of systemic antifungal agents in haematology and oncology - MAAMy

开始日期2021-04-01

申办/合作机构-

100 项与副球菌病相关的临床结果

登录后查看更多信息

100 项与副球菌病相关的转化医学

登录后查看更多信息

0 项与副球菌病相关的专利（医药）

登录后查看更多信息

2,020

项与副球菌病相关的文献（医药）

2025-04-01·Molecular Aspects of Medicine

When to suspect and how properly early detect and treat patients with endemic mycoses

Review

作者: Santos, Daniel Wagner de C L ; Peçanha-Pietrobom, Paula M ; Colombo, Arnaldo L ; Caceres, Diego H

Endemic mycoses are caused by dimorphic fungi and eventually molds, as the case of implantation mycoses. In general, these diseases are acquired through trauma or inhalation of fungal elements in the environment, and less frequently by zoonotic acquisition or transmitted during organ transplantation. The target population for endemic mycoses is usually represented by normal hosts with low-income and intensive outdoor activities. Awareness of these diseases remains limited, even in regions with high prevalence, resulting in delayed diagnosis, and affecting the quality of life and outcomes of patients who suffer from these entities. In this review, we summarized relevant information about epidemiological, clinical, diagnostic, and treatment aspects of the most common endemic mycoses, including blastomycosis, coccidioidomycosis, histoplasmosis, paracoccidioidomycoses, talaromycosis, and implantation mycoses. The main goal of this review is to provide key concepts in terms of when to suspect, how early diagnose, and properly treat patients with these mycoses.

2025-03-27·Open Forum Infectious Diseases

Paracoccidioidomycosis as a Manifestation of Immune Reconstitution Inflammatory Syndrome in an HIV Patient: An Uncommon Presentation

Article

作者: Lima, Luiz A A ; Carneiro, Ana H P C ; Djahjah, Maria Célia ; Mendes, Isabel C M ; Lóta, Francine C ; Paschoal, Marilene M ; Silva, Amanda P O ; Souza, Sergio A L

AbstractA 50-year-old HIV-positive woman, nonadherent to antiretroviral therapy, developed asthenia, weight loss, and lymphadenopathy after restarting treatment. Imaging revealed adenopathies and a breast nodule, with biopsies confirming Paracoccidioides brasiliensis. Despite initial therapy failure (trimethoprim-sulfamethoxazole), liposomal amphotericin, corticosteroids, and a regimen change led to partial improvement until a psoas abscess required drainage, ultimately stabilizing her condition.

2025-02-14·Medicine

First case report of long-term latent infection paracoccidioidomycosis in China

Article

作者: Wu, Shaoling ; Dong, Haiping ; Tang, Guidan ; Liang, Xiaocheng ; Wang, Weiyong ; Liang, Feng ; Hu, Jinxing ; Liao, Weixiang ; Li, Hua ; Pan, Yanshan ; Cao, Zhizhong ; Li, Donghai ; Feng, Jingyuan ; Zhou, Wei

Rationale:Although paracoccidioidomycosis is one of the most prevalent endemic mycoses in Latin American countries, where at least 10 million people are infected, the prevalence of paracoccidioidomycosis in China remains unknown because no related case has been reported, and its diagnosis is extremely challenging for local clinicians because of the complexity of disease progression and lack of specific evidence.Patient concerns:Here, we report the first case of PCM in a male patient with a long-term latent infection in China.Diagnosis:The results of special staining, immunohistochemistry, lymph node biopsy pathology, and metagenomic second-generation sequencing indicated that the patient was infected with Paracoccidioides brasiliensis.Interventions:In this case, the patient was administered voriconazole 200 mg twice daily.Outcomes:After continuous treatment for 6 months, the patient’s symptoms improved significantly, and the medication was discontinued. The outpatient follow-up revealed no discomfort.Lessons:This case is of great value for the early diagnosis, treatment, and prevention of the spread of this emerging infectious disease in China.

项与副球菌病相关的新闻（医药）

2022-11-01

·药时代

红斑狼疮及多疾病领域的潜力靶点：BDCA-2

晶云药物全球商务部负责人陈岑博士：诚邀您出席2022第三届中国新药CMC高峰论坛！皮肤型红斑狼疮（CLE）和系统性红斑狼疮（SLE）是红斑狼疮的两种不同类型。SLE除了像CLE一样累及皮肤外，还会伴有肾脏、心脏、肺、血液、神经等多个器官和系统受累，免疫系统的异常贯穿了SLE整个发病过程。而BDCA-2对两种类型红斑狼疮的治疗具有重大意义。01靶点概述血液树突状细胞抗原2（BDCA-2），也被命名为CLEC4C或CD303，在浆细胞样树突状细胞（PDC）上唯一表达，是一种II型c型凝集素。BDCA-2结构[1]与BCR信号转导类似，BDCA-2可能是通过与其网格蛋白介导的内吞作用的内化有关，BDCA-2信号传导诱导酪氨酸磷酸化和酪氨酸激酶依赖性钙内流，交联BDCA-2导致受刺激的PDC中 I 型干扰素（IFN-I）产生受到抑制，而PDC是主要的IFN-I生成者。另外BDCA-2信号传导导致 IFN-I 基因和 IFN-I 反应基因的转录水平降低，表明受刺激的 PDC 对 IFN-I 产生的抑制至少在转录水平上受到调节。众所周知，PDC 产生的 IFN-I 被认为是红斑狼疮患者的主要病理生理因素。02信号通路BDCA-2胞外部分的c型碳水化合物识别域包含典型的c型动物凝集素的特征基序，与甘露糖、葡萄糖或N-乙酰葡糖胺结合。由于BDCA-2的胞内部分缺少任何已知的信号基序，但是BDCA-2与FcR γ链存在免疫共沉淀，因此与FcR γ链相关的BDCA-2在B细胞抗原受体（BCR）样信号体中发出信号。触发BDCA-2会导致酪氨酸激酶（Syk）的激活、B细胞连接蛋白（SLP65）的募集和磷脂酰肌醇特异性磷酯酶（PLCγ2）的活性，PLCγ2的激活可能诱导钙流入并在PDC中充当负调节剂，介导IFN-Ⅰ抑制并通过BDCA2触发减少NFKB的激活。BDCA-2通路[2]有多项研究表明，活动期SLE患者血清中IFN-Ⅰ的水平与健康人相比明显升高，并与疾病严重程度和进展相关。前文提到，BDCA-2的信号传导会使得PDC产生IFN-Ⅰ受到抑制，且不受IFN-Ⅰ其他诱导刺激的影响，因此BDCA-2相关的药物研发，可以通过减少IFN-Ⅰ的产生来达到治疗SLE的目的。03在研格局目前，全球用于红斑狼疮治疗的BDCA-2药物并不多，进展最快的是渤健生物开发的BDCA2单抗BIIB059（Litifilimab），通过抑制BDCA-2，减少IFN-Ⅰ等炎性细胞因子的产生，从而达到治疗红斑狼疮的目的。BIIB059是全球唯一一款进入临床的BDCA-2单抗，其中SLE治疗在美国已经推进至临床III期，CLE治疗推进至临床II期。值得注意的是，BIIB059还为CLE的治疗带来了新希望。今年7月，关于BIIB059治疗CLE的疗效和安全性的II期临床试验发表于“New England Journal of Medicine”(IF=176.079)，试验通过对132名18-75岁的CLE患者进行随机分组治疗。结果表明该靶点抗体药可以改善CLE患者的皮肤病活动性，对CLE的治疗效果高于安慰剂治疗，从基线到第16周，CLASI-A评分的最小二乘平均值（±SE）百分比变化：50mg litifilimab组为-38.8±7.5；150mg litifilimab组为-47.9±7.4；450mg litifilimab组中-42.5±5.5；安慰剂组为-14.5±6.4。重复测量回归模型CLASI-A评分的基线变化百分比分析结果04其他应用除红斑狼疮外，BDCA-2在其他免疫疾病和血液瘤中也表现了巨大潜力。在一些慢性炎症中，DCs的亚群失调或增加，包括子宫内膜异位症、慢性鼻炎伴鼻息肉、哮喘、颈动脉硬化、I型糖尿病、组织细胞坏死性淋巴结炎、克雅氏病和II型糖尿病患者伴牙周炎。在感染性疾病的研究中。EBV、人类免疫缺陷病毒（HIV）、寨卡病毒和某些真菌感染（例如染色芽生菌病和副球孢子菌病）中，均涉及到BDCA-2信号传导。在自免疾病中，除红斑狼疮，干燥综合征、斑秃、白癜风和多发性肌炎等疾病也与BDCA-2有关，如在患有多发性肌炎、皮肌炎和其他炎症性肌病的患者的肌肉纤维中发现了高水平的 BDCA-2(+) pDC。在血液瘤中，pDC 的恶性增殖也与某些血液瘤的发病机制有关，特别是原始浆细胞样树突状细胞肿瘤（BPDCN）和伴有 pDC 克隆扩增的急性骨髓性白血病（pDC-AML）。此外，研究表明BDCA-2也可能在实体瘤治疗中发挥作用，如黑色素瘤和非小细胞肺癌等。小结：目前，对于BDCA-2药物的研究并不多，且主要适应症为红斑狼疮，但众多研究已经表明了BDCA-2在多领域疾病治疗中的潜力，也期待渤健的Litifilimab治疗CLE的临床研究继续带来好消息。参考：1.https://structure-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/ 2.DOI:10.1080/10428194.2021.19751923.DOI: 10.1056/NEJMoa21180244.https://doi-org.libproxy1.nus.edu.sg/10.1002/eji.2007377115.https://pharmsnap-zhihuiya-com.libproxy1.nus.edu.sg/ 封面图来源：123rf版权声明/免责声明本文为授权转载文章，版权归拥有者。仅供感兴趣的个人谨慎参考，非商用，非医用、非投资用。欢迎朋友们批评指正！衷心感谢！文中图片、视频为授权正版作品，或来自微信公共图片库，或取自公司官网/网络根据CC0协议使用，版权归拥有者。任何问题，请与我们联系（电话：13651980212。微信：27674131。邮箱：contact@drugtimes.cn）。衷心感谢！博腾股份工艺化学服务部负责人，技术平台负责人史峰博士：诚邀您出席2022第三届中国新药CMC高峰论坛！前FDA检查官、Live Oak Quality Assurance 创始人兼总裁Peter Baker 先生：诚邀您出席2022第三届中国新药CMC高峰论坛！666位嘉宾将出席盛会！2022第三届中国新药CMC高峰论坛最终日程113本新药好书免费送：《新药的故事1-3》《十亿美元分子》《药明康德经典译丛》……中国新药CMC高峰论坛“十三邀”！点击这里，准时参会！

抗体